OncoSec Medical Incorporated (ONCS)’s Financial Results Comparing With Tiziana Life Sciences PLC (NASDAQ:TLSA)

This is therefore a contrasting of the institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations in OncoSec Medical Incorporated (NASDAQ:ONCS) and Tiziana Life Sciences PLC (NASDAQ:TLSA). The two are both Biotechnology companies that compete with one another.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
OncoSec Medical Incorporated N/A 0.00 40.81M -1.01 0.00
Tiziana Life Sciences PLC N/A 0.00 N/A -0.07 0.00

Demonstrates OncoSec Medical Incorporated and Tiziana Life Sciences PLC earnings per share (EPS), top-line revenue and valuation.


Table 2 shows us OncoSec Medical Incorporated and Tiziana Life Sciences PLC’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
OncoSec Medical Incorporated 0.00% -179.5% -144.8%
Tiziana Life Sciences PLC 0.00% 0% 0%

Analyst Ratings

OncoSec Medical Incorporated and Tiziana Life Sciences PLC Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
OncoSec Medical Incorporated 0 1 0 2.00
Tiziana Life Sciences PLC 0 0 0 0.00

Insider and Institutional Ownership

The shares of both OncoSec Medical Incorporated and Tiziana Life Sciences PLC are owned by institutional investors at 12.4% and 0% respectively. Insiders owned 2.4% of OncoSec Medical Incorporated shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
OncoSec Medical Incorporated -0.59% 1.77% -43.9% -40.05% -48.82% -46.14%
Tiziana Life Sciences PLC -10.96% 0% 0% 0% 0% -16.29%

For the past year Tiziana Life Sciences PLC has weaker performance than OncoSec Medical Incorporated


Tiziana Life Sciences PLC beats on 5 of the 7 factors OncoSec Medical Incorporated.

OncoSec Medical Incorporated, a biotechnology company, designs, develops, and commercializes gene therapies, therapeutics, and proprietary medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer in the United States. Its lead product candidate is the ImmunoPulse IL-12, which is in Phase II clinical trial for various indications, including metastatic melanoma and triple negative breast cancer. ImmunoPulse is an electroporation delivery device used in combination with the companyÂ’s therapeutic product candidates, including DNA plasmids that encode for immunologically active agents, and to deliver the therapeutic directly into the tumor and promote an inflammatory response against the cancer. The company also has completed two Phase II studies for products, such as OMS-I100 in metastatic melanoma and OMS-I110 in merkel cell carcinoma. It has a clinical collaboration with the University of California, San Francisco to evaluate the safety and efficacy of ImmunoPulse IL-12 in combination with KEYTRUDA (pembrolizumab) in patients with low tumor-infiltrating lymphocyte; and a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the combination of OncoSec's ImmuoPulse IL-12 with MerckÂ’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) in a Phase II clinical trial referred to as PISCES. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in San Diego, California.